Comparative Pharmacology
Head-to-head clinical analysis: EXFORGE versus RAU SED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXFORGE versus RAU SED.
EXFORGE vs RAU-SED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Exforge is a combination of amlodipine, a dihydropyridine calcium channel blocker, and valsartan, an angiotensin II receptor blocker. Amlodipine inhibits calcium influx across cardiac and vascular smooth muscle cell membranes, causing vasodilation. Valsartan selectively blocks the binding of angiotensin II to AT1 receptors, leading to vasodilation and reduced aldosterone secretion.
Reserpine depletes catecholamines (norepinephrine, dopamine) from adrenergic nerve endings by binding to and inhibiting the vesicular monoamine transporter (VMAT), preventing neurotransmitter storage and leading to depletion of catecholamines.
One tablet orally once daily. Initial dose: 5/160 mg or 5/320 mg. Titrate based on blood pressure response. Maximum dose: 10/320 mg once daily.
Initial: 0.5 mg orally once daily; maintenance: 0.1-0.25 mg orally once daily.
None Documented
None Documented
Amlodipine: terminal elimination half-life is 30-50 hours (mean ~35 h), supporting once-daily dosing. Valsartan: terminal half-life is approximately 6 hours, with the combination product dosed once daily due to amlodipine's long half-life.
Terminal elimination half-life: 45-90 hours (average 60 hours); clinical context: requires 5-7 days to reach steady-state; prolonged half-life may lead to cumulative effects
Valsartan is primarily eliminated via biliary excretion (83%) in feces as unchanged drug; renal excretion accounts for 13% (mostly unchanged). Amlodipine is extensively metabolized in the liver, with 60% of metabolites excreted renally and 20-25% in feces as unchanged drug.
Renal (60-70% as unchanged drug and metabolites); fecal (20-30% via biliary elimination)
Category C
Category C
Antihypertensive
Antihypertensive